-
Product Insights
Innovations in Conventional Radio Frequency Ablation Catheters – Global Pipeline Summary
GlobalData's Medical Devices sector report, "Innovations in Conventional Radio Frequency Ablation Catheters - Global Pipeline Summary" provides comprehensive information about the Conventional Radio Frequency Ablation Catheters pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Conventional Radio Frequency Ablation Catheters report provides key information and data related to: Extensive coverage of the Conventional Radio Frequency Ablation Catheters under development Review details of major pipeline products which include...
-
Product Insights
MOLN – Onnaing Radio Pharmaceutical Lead-212 Manufacturing Plant – Hauts-de-France
The MOLN – Onnaing Radio Pharmaceutical Lead-212 Manufacturing Plant – Hauts-de-France involves the construction of a new radio pharmaceutical manufacturing plant on 3,000m2 area in Onnaing Commune, Valenciennes City, Nord Department, Hauts-de-France Region, France. Equip yourself with the essential tools needed to make informed and profitable decisions with our MOLN – Onnaing Radio Pharmaceutical Lead-212 Manufacturing Plant – Hauts-de-France report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RiMO-401 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RiMO-401 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RiMO-401 in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FF-10158 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FF-10158 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FF-10158 in Pancreatic Ductal Adenocarcinoma Drug Details: 177LuFF-10158 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FF-10158 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FF-10158 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FF-10158 in Adenocarcinoma Of The Gastroesophageal Junction Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FF-10158 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FF-10158 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FF-10158 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: 177LuFF-10158...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 177Lu-Satoreotide in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 177Lu-Satoreotide in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 177Lu-Satoreotide in Small-Cell Lung Cancer Drug Details: 177Lu-satoreotide (OPS-201, SOMther)...
-
Thematic Analysis
NewTelecom Infrastructure Sector Scorecard, Q1 2024 Update – Thematic Intelligence
The thematic screen of GlobalData’s telecom infrastructure sector scorecard is led by global vendors that score well in the themes related to cloud computing (e.g., programmable infrastructure, edge computing, private networks), 5G, and artificial intelligence (AI). The leaders include US network vendor Cisco, European radio access network (RAN) specialists Nokia and Ericsson, and innovative new entrants such as Mavenir and Rakuten, which is reaping the benefits of acquiring Open RAN vendor Altiostar.
-
Product Insights
NewCell>Point LLC Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Cell>Point LLC Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Cell>Point LLC (Cell>Point) is a bio pharmaceutical company that offers therapeutic compounds. The company develops and markets intra-nuclear molecular imaging and therapeutic compounds. It provides ethylenedicysteine drug conjugate technology, cancer imaging, cardiology imaging, intra-nuclear therapy, beta cell imaging, radio and chemotherapy delivery system, n4-technology, and dual agent technology. Cell>Point provides n4-(tetraaza cyclopentadiene) technology to image and treat certain neurological diseases...
-
Company Insights
NewKardium Inc Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our Kardium Inc Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. Kardium Inc (Kardium) is a medical device company that develops ground breaking medical device for the diagnosis and treatment of atrial fibrillation. The company offers the globe mapping and ablation system, an investigational medical device used in the diagnosis and treatment of atrial fibrillation. Its globe mapping and ablation system contains the globe catheter, the globe software console and the...